Arjunetin

Arjunetin at a Glance

Arjunetin is a triterpenoid saponin — a sugar-bearing glycoside built on the sapogenin arjungenin — found in the stem bark of arjuna (Terminalia arjuna), the South Asian tree whose bark is a classical Ayurvedic cardiac tonic ^{1Reference 1Amalraj A · 2017ReviewMedicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: A reviewView study →}. Chemically it belongs to a small family of closely related oleanane-type bark saponins (arjunetin and the arjunglucosides I–III), all sharing the same pentacyclic skeleton as oleanolic acid and differing in their oxygenation and sugars.

As an isolated molecule arjunetin is barely studied. The human evidence for arjuna is for whole bark powder or water/alcohol bark extract — not for arjunetin on its own — and no clinical trial has tested the purified saponin. What isolate data exist are a handful of laboratory and computational studies. This page states plainly where the data stop.

Arjunetin, an Arjuna Saponin

Arjunetin is the glucoside of arjungenin: arjungenin is the free sapogenin (aglycone), and attaching a glucose to it gives arjunetin. Recent biosynthetic work made this concrete — the glycosyltransferase UGT73FB1 glucosylates the C-28 carboxyl of arjuna triterpenoids and produces arjunetin (with arjunglucoside II) as a major glucosyl-ester product in the saponin-rich bark ^{2Reference 2Vyas P et al. · 2025UGT73FB1 contributes to scaffold-selective biosynthesis of triterpenoid glucosyl esters in saponin-rich bark of arjuna treeView study →}. Arjunetin therefore sits alongside its aglycone arjungenin and the related triterpene acids arjunolic acid and arjunic acid as part of arjuna’s characteristic oleanane fraction.

The real isolate signal for arjunetin is thin, and mostly not therapeutic:

• Plant defence (the one study on arjunetin itself). Purified arjunetin was the strongest feeding-deterrent and growth inhibitor among arjuna bark compounds tested against larvae of the pest moth Spilarctia obliqua, though it did not deter egg-laying ^{3Reference 3Singh DV et al. · 2004Arjunetin from Terminalia arjuna as an insect feeding-deterrent and growth inhibitorView study →}. This fits the general role of triterpene saponins as bitter, membrane-active chemical defences in bark.
• A sibling saponin’s antiparasitic result. A close structural relative, arjunglucoside I, reduced parasite burden in Leishmania-infected animals (more so when delivered in nanoparticles) ^{4Reference 4Tyagi R et al. · 2005Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasisView study →} — an animal result for a different molecule, not arjunetin.
• A computational prediction. An in-silico screen flagged arjunetin and arjunglucoside I as oleanane glycosides predicted to inhibit acetylcholinesterase and cross the blood–brain barrier — calculated only, with no wet-lab confirmation ^{5Reference 5Stępnik K et al. · 2023Molecular and pharmacokinetic aspects of the acetylcholinesterase-inhibitory potential of the oleanane-type triterpenes and their glycosidesView study →}.
• Present but not the active one. When four arjuna bark compounds were profiled for cytotoxicity, arjunetin was isolated but it was arjunic acid, not arjunetin, that was significantly active ^{7Reference 7Saxena M et al. · 2007Cytotoxic agents from Terminalia arjunaView study →}.

Plainly stated: no cardiovascular study has ever tested arjunetin as an isolate. Its cardiac reputation is inherited from whole arjuna bark ^{1Reference 1Amalraj A · 2017ReviewMedicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: A reviewView study →}.

What It's Used For

The evidence for arjunetin is class-level and sparse. It splits by whether the thing tested was arjunetin itself, a sibling saponin, whole bark, or a computer model.

Evidence by IndicationStrength of support · Beta

Support is an experimental score weighted by study type (human > animal > in vitro) and volume — a beta, not a validated metric. Every score here is low: arjunetin has no human isolate data, and most rows lean on whole bark or a sibling saponin. Read the per-row basis.

01Cardiotonic / cardiovascularShaky20%Class-level only — whole-bark human data, no arjunetin isolate study ^{1Reference 1Amalraj A · 2017ReviewMedicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: A reviewView study →}

02Antiparasitic (arjuna saponins)Shaky16%One animal study — of the sibling saponin arjunglucoside I, not arjunetin ^{4Reference 4Tyagi R et al. · 2005Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasisView study →}

03Insect antifeedant / plant defenceShaky12%Direct arjunetin isolate lab assay — but ecological, not therapeutic ^{3Reference 3Singh DV et al. · 2004Arjunetin from Terminalia arjuna as an insect feeding-deterrent and growth inhibitorView study →}

Mechanisms

The load-bearing caveat: none of these is a demonstrated human mechanism for arjunetin. The inotropy row is an analogy, the AChE row is a computer prediction, and the antiparasitic row belongs to a different molecule.

Pharmacokinetics

Like triterpene saponins generally, arjunetin is a large, sugar-bearing, poorly lipid-soluble molecule and is expected to be poorly absorbed after oral intake. Gut bacteria and stomach acid typically hydrolyse such saponins to their sapogenin — here, arjungenin — so much of any swallowed arjunetin likely reaches the circulation, if at all, as the aglycone rather than the intact glycoside. No human pharmacokinetic study of arjunetin exists. A single in-silico analysis predicted arjunetin could cross the blood–brain barrier and inhibit acetylcholinesterase, but these are calculated parameters, not measured ones ^{5Reference 5Stępnik K et al. · 2023Molecular and pharmacokinetic aspects of the acetylcholinesterase-inhibitory potential of the oleanane-type triterpenes and their glycosidesView study →}. This poor-bioavailability expectation is the main reason the in-vitro potency of an isolated saponin should not be read as oral activity.

Clinical Trials

No clinical trial has tested isolated arjunetin. All human evidence attached to arjuna belongs to whole bark powder or bark extract and lives on the arjuna herb page, not here.

Last checked: July 2026.

Isolate vs. Plant Studies

This molecule sits almost entirely on the plant side. Every human result for arjuna used the whole bark or a bark extract — never purified arjunetin ^{1Reference 1Amalraj A · 2017ReviewMedicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: A reviewView study →}. The isolate literature is (a) a plant-defence insect bioassay of arjunetin itself ^{3Reference 3Singh DV et al. · 2004Arjunetin from Terminalia arjuna as an insect feeding-deterrent and growth inhibitorView study →}, (b) an animal antiparasitic study of the sibling saponin arjunglucoside I ^{4Reference 4Tyagi R et al. · 2005Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasisView study →}, and (c) an in-silico prediction ^{5Reference 5Stępnik K et al. · 2023Molecular and pharmacokinetic aspects of the acetylcholinesterase-inhibitory potential of the oleanane-type triterpenes and their glycosidesView study →}. The honest read: arjunetin is a marker constituent of a well-used cardiac herb whose benefits cannot presently be assigned to it specifically. Where a bark saponin was isolated and tested for a therapeutic endpoint (cytotoxicity), arjunetin was present but arjunic acid, not arjunetin, was the active compound ^{7Reference 7Saxena M et al. · 2007Cytotoxic agents from Terminalia arjunaView study →}.

Major Natural Sources

Arjunetin is characteristic of arjuna (Terminalia arjuna) stem bark, where it occurs within the minor triterpene-saponin fraction (total triterpenoids are under ~1% of the bark) ^{1Reference 1Amalraj A · 2017ReviewMedicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: A reviewView study →}. It and its close relatives (the arjunglucosides) are also reported across other Terminalia species, which is why they turn up in analyses of the Ayurvedic fruit blend triphala ^{6Reference 6Avula B et al. · 2013Simultaneous determination and characterization of tannins and triterpene saponins from the fruits of various species of Terminalia and Phyllanthus emblica using a UHPLC-UV-MS method: application to triphalaView study →}.

Source	Part	Notes
Arjuna (Terminalia arjuna)	Stem bark	Primary source; a saponin of the <1% triterpenoid fraction 1Reference 1Amalraj A · 2017ReviewMedicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: A reviewView study →
Other Terminalia spp. (e.g. in triphala)	Fruit	Arjunetin + arjunglucosides detected analytically across the genus 6Reference 6Avula B et al. · 2013Simultaneous determination and characterization of tannins and triterpene saponins from the fruits of various species of Terminalia and Phyllanthus emblica using a UHPLC-UV-MS method: application to triphalaView study →

No quantified bark concentration for arjunetin specifically has been published — a gap tracked for a later pass. Co-occurring arjuna bark compounds include the triterpene acids arjunolic acid and arjunic acid, the sapogenin arjungenin, and the sterol beta-sitosterol; the skeleton is the same oleanane frame as oleanolic acid.

Discovery & Synthesis

Arjunetin was isolated from arjuna bark in the course of twentieth-century Indian phytochemical work on the tree’s triterpene saponins; a precise first-isolation date is not well documented here. Structurally it is now understood as a C-28 glucosyl ester of arjungenin: recent biosynthetic work identified the glycosyltransferase UGT73FB1, which glucosylates the C-28 carboxyl of arjuna triterpenoids and produces arjunetin (and arjunglucoside II) as major products in the saponin-rich bark ^{2Reference 2Vyas P et al. · 2025UGT73FB1 contributes to scaffold-selective biosynthesis of triterpenoid glucosyl esters in saponin-rich bark of arjuna treeView study →}. No total chemical synthesis of arjunetin is documented; it is obtained by extraction, and as a research reference material it is isolated chromatographically from Terminalia extracts ^{6Reference 6Avula B et al. · 2013Simultaneous determination and characterization of tannins and triterpene saponins from the fruits of various species of Terminalia and Phyllanthus emblica using a UHPLC-UV-MS method: application to triphalaView study →}.

Patents: not yet researched.

Toxicity & Safety

Arjunetin carries a low flag, with the honest caveat that this reflects arjuna’s traditional record, not data on the pure molecule. Whole arjuna bark has a long history of use and is generally well tolerated at the doses studied; as a large saponin, arjunetin is also poorly absorbed orally, which limits systemic exposure. But the isolated saponin has not been through any human safety study, and triterpene saponins as a class are membrane-active — locally irritant and haemolytic to red cells in vitro at high concentration — so an isolate flag cannot simply be read off the herb’s safety.

Reproductive and developmental safety of isolated arjunetin has not been characterised. Pregnancy and lactation decisions belong to the arjuna herb or a finished product, where intake is actually decided, not to this molecule page.

Safety at a Glance

✅ Low / no toxicity

• Traditional arjuna bark is well tolerated. Long Ayurvedic use of the whole bark at studied doses, within which arjunetin is a minor constituent.
• Poorly absorbed orally. As a large saponin glycoside, systemic exposure to intact arjunetin is expected to be low.
• No isolate safety data. Purified arjunetin has not been tested for human safety, genotoxicity, or reproductive effects.
• Saponin-class effects. Triterpene saponins are membrane-active — locally irritant and haemolytic in vitro at high concentration; relevance to dietary/herbal exposure is unquantified.

Dosage

There is no established dose for isolated arjunetin — it is not sold or studied as a stand-alone compound. Human dosing figures belong to arjuna bark, not the saponin: cardiovascular research has typically used ~500 mg of bark powder three times daily, or ~750 mg of a standardised aqueous bark extract twice daily ^{1Reference 1Amalraj A · 2017ReviewMedicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: A reviewView study →}. Arjunetin is only a minor fraction of that material.

These are herbal research figures, not a personal recommendation, and they describe the whole bark rather than this molecule.

References

1. Amalraj A, Gopi S (2017). Medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: A review. Journal of Traditional and Complementary Medicine. https://pubmed.ncbi.nlm.nih.gov/28053890/
2. Vyas P, Srivastava P, Srivastava G, et al. (2025). UGT73FB1 contributes to scaffold-selective biosynthesis of triterpenoid glucosyl esters in saponin-rich bark of arjuna tree. The Plant Journal. https://pubmed.ncbi.nlm.nih.gov/40227097/
3. Singh DV, Gupta MM, Tripathi AK, Prajapati V, Kumar S (2004). Arjunetin from Terminalia arjuna as an insect feeding-deterrent and growth inhibitor. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/15022165/
4. Tyagi R, Lala S, Verma AK, et al. (2005). Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. Journal of Drug Targeting. https://pubmed.ncbi.nlm.nih.gov/16036304/
5. Stępnik K, Kukula-Koch W, Płaziński W (2023). Molecular and pharmacokinetic aspects of the acetylcholinesterase-inhibitory potential of the oleanane-type triterpenes and their glycosides. Biomolecules. https://pubmed.ncbi.nlm.nih.gov/37759757/
6. Avula B, Wang YH, Wang M, Shen YH, Khan IA (2013). Simultaneous determination and characterization of tannins and triterpene saponins from the fruits of various species of Terminalia and Phyllanthus emblica using a UHPLC-UV-MS method: application to triphala. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/23299756/
7. Saxena M, Faridi U, Mishra R, et al. (2007). Cytotoxic agents from Terminalia arjuna. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/18008199/

View all 7 references▾